UNSPSC 51382701: Oxindanac

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZY400R3BNT. European Medicines Agency schedules Oxindanac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09532MIG. Oxindanac generally arises in the molecular formula C17H14O4.

The term OXINDANAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) OXINDANAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, OXINDANAC remains the US FDA Preferred Term for this commodity. Oxindanac bears US NLM identifiers UMLS ID C0069768 and NCI Concept Code C66268. SMILES: OC(=O)C1CCC2C1CC(O)C(C2)C(=O)C1CCCCC1.

UNSPSC 51382701 Oxindanac is a Commodity code that does not accurately reflect the state and local procurement activity tagged under it. The three recent opportunities in the source—naloxone procurement by Seminole County, Florida; a Texas HHS Commission RFI on direct-to-manufacturer prescriptions; and a Minnesota cooperative purchasing alliance RFP for generic pharmaceuticals and OTC products—involve naloxone, prescription fulfillment programs, and broad-spectrum generic drug sourcing, none of which align with oxindanac, an oxindole derivative pharmaceutical with a specific clinical profile. The code shows a mismatch between its nominal scope and the work actually being solicited under it in state and local procurement.

The recent opportunities do reveal activity across state health agencies, county health departments, and cooperative purchasing consortia, with issuing bodies including Seminole County (Florida), the Texas Health and Human Services Commission, and the Minnesota Department of Administration on behalf of the Minnesota Multistate Cooperative Purchasing Alliance. Geographic spread includes Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon. Representative solicitations include Seminole County's IFB60459723LAS (due Jul 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; Texas HHS RFI HHS0017013 (due Apr 3, 2026) exploring direct-to-manufacturer prescription contracting; and MMCAP's RFP S1070000015802 (due Mar 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers. Until the code's tagging is corrected or recent opportunities using the code's actual scope are posted, the code shows little actionable signal for business development under its stated pharmaceutical definition.